Search for: "Breckenridge Pharmaceutical, Inc." Results 1 - 20 of 23
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 May 2017, 8:27 pm by Patent Docs
Breckenridge Pharmaceutical, Inc., illustrates the risks a litigant can take when agreeing to stipulation in an effort at least to reduce litigation costs and issues presented at trial. [read post]
1 Jun 2014, 9:25 am by Patent Docs
• Defendants: Breckenridge Pharmaceutical Inc.; Natco Pharma Ltd. [read post]
18 Jan 2015, 9:06 pm by Patent Docs
Breckenridge Pharmaceutical, Inc.... [read post]
6 Nov 2011, 9:18 pm by Patent Docs
Breckenridge Pharmaceutical Inc. et al. 1:11-cv-01070; filed November 2, 2011 in the District Court of Delaware • Plaintiffs: Cephalon Inc.; Cephalon France • Defendants: Breckenridge Pharmaceutical Inc.; Natco Pharma Ltd. [read post]
23 Apr 2007, 11:14 am
Breckenridge Pharmaceutical, Inc. v. [read post]
2 Mar 2019, 9:48 pm by Patent Docs
Breckenridge Pharmaceutical, and Supernus Pharmaceuticals, Inc. v.... [read post]
6 May 2017, 10:11 am by Lawrence B. Ebert
(“Braintree”) appealsfrom the Southern District of New York’s summary judgmentthat Breckenridge Pharmaceutical, Inc. [read post]
6 Feb 2019, 5:15 pm by Scott McKeown
Statutory Right to Appeal for Joined Parties In Mylan Pharmaceuticals Inc. v. [read post]
20 Sep 2018, 6:53 am by Rebecca Tushnet
Nivagen Pharmaceuticals, Inc., 2018 WL 4409350, No. 2:17-cv-01974-MCE-GGH (E.D. [read post]
3 Apr 2018, 12:26 pm by Rebecca Tushnet
Nivagen Pharmaceuticals, Inc., No. 17-cv-01974-MCE-GGH, 2018 WL 1567820 (E.D. [read post]
2 Jan 2008, 9:05 pm
Drug Impairment Detection Services, LLC Breckenridge Pharmaceutical, Inc. v. [read post]
22 Jul 2009, 6:05 am
(PatLit) Levaquin (Levofloxacin) – US: CAFC awards only partial costs where depositions used in multiple cases from different district courts: Ortho-McNeil Pharmaceutical, Inc. v. [read post]
17 Jan 2008, 10:00 pm
: (Against Monopoly),Structuring a decentralized world - Institute for Ethics and Emerging Technologies: The necessity of open biotechnology: (Patent Lens),A skeptical look at the Automated Content Access Protocol: (Ars Technica),5 practical things to incorporate in a corporate IP strategy: (IP ThinkTank), Legal models for online content enforcement: (OpenContentLawyer),Germany, Chinese copies and misdirected ‘strategy': (IP… [read post]